apixaban,dabigatran,rivaroxaban,edoxaban
pfizer,bms,boehringer ingelheim,bayer,Daiichi Sankyo
['dabigatran', 'apixaban', 'rivaroxaban']
my fav oral abstract #uegw2022 on risk of ugib in #doac users by from conclusion: rivaroxaban was associated with a significantly higher risk of severe ugib than apixaban and dabigatran. #gibleed #gitwitter #medtwitter 
Gastroenterologist, #IBS research | Sec-Gen @ANMA_i | President, IBS Support Group Singapore I Secretary, NFDD I Cochair, Social Media @RomeGastroPsy I ??? I